KDR and neoplasm: Previous studies have shown that bevacizumab inhibits VEGF signaling and reduces immunosuppressive cells and that multitarget TKIs block the VEGFR/PDGFR/FGFR pathway, promoting vascular normalization and alleviating tumor immune escape (16, 50, 51, 61).